[go: up one dir, main page]

WO2018151840A3 - Methods and compositions for treating malignant tumors - Google Patents

Methods and compositions for treating malignant tumors Download PDF

Info

Publication number
WO2018151840A3
WO2018151840A3 PCT/US2018/000054 US2018000054W WO2018151840A3 WO 2018151840 A3 WO2018151840 A3 WO 2018151840A3 US 2018000054 W US2018000054 W US 2018000054W WO 2018151840 A3 WO2018151840 A3 WO 2018151840A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
mammal
methods
malignant tumors
kras
Prior art date
Application number
PCT/US2018/000054
Other languages
French (fr)
Other versions
WO2018151840A2 (en
Inventor
Wenbin Ying
Kenjirou Minomi
Jihua Liu
Li Wang
Bharat Majeti
Roger Adami
Original Assignee
Nitto Denko Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/434,318 external-priority patent/US10792299B2/en
Application filed by Nitto Denko Corporation filed Critical Nitto Denko Corporation
Priority to JP2018535394A priority Critical patent/JP2019508379A/en
Publication of WO2018151840A2 publication Critical patent/WO2018151840A2/en
Publication of WO2018151840A3 publication Critical patent/WO2018151840A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention provides methods and compositions for preventing, treating or ameliorating one or more symptoms of a malignant tumor associated with KRAS mutation in a mammal in need thereof, by identifying a tumor cell in the mammal, the tumor cell comprising at least one of: (i) a mutation of the KRAS gene, and (ii) an aberrant expression level of KRAS protein; and administering to the mammal a therapeutically effective amount of a composition comprising one or more RNAi molecules that are active in reducing expression of GST-π.
PCT/US2018/000054 2017-02-16 2018-02-16 Methods and compositions for treating malignant tumors Ceased WO2018151840A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2018535394A JP2019508379A (en) 2017-02-16 2018-02-16 Therapeutic method and therapeutic composition for malignant tumor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/434,318 US10792299B2 (en) 2014-12-26 2017-02-16 Methods and compositions for treating malignant tumors associated with kras mutation
US15/434,318 2017-02-16

Publications (2)

Publication Number Publication Date
WO2018151840A2 WO2018151840A2 (en) 2018-08-23
WO2018151840A3 true WO2018151840A3 (en) 2018-10-11

Family

ID=63170424

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/000054 Ceased WO2018151840A2 (en) 2017-02-16 2018-02-16 Methods and compositions for treating malignant tumors

Country Status (2)

Country Link
JP (2) JP2019508379A (en)
WO (1) WO2018151840A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021046480A1 (en) * 2019-09-06 2021-03-11 The Regents Of The University Of California Nucleic acid-mediated delivery of therapeutics

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160186183A1 (en) * 2014-12-26 2016-06-30 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007051303A1 (en) * 2005-11-02 2007-05-10 Protiva Biotherapeutics, Inc. MODIFIED siRNA MOLECULES AND USES THEREOF
WO2007134161A2 (en) * 2006-05-11 2007-11-22 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the pcsk9 gene
AU2008270209B2 (en) * 2007-07-05 2012-05-17 Arrowhead Pharmaceuticals, Inc. dsRNA for treating viral infection
US20160187319A1 (en) * 2014-12-26 2016-06-30 Nitto Denko Corporation Cell death-inducing agent, cell growth-inhibiting agent, and pharmaceutical composition for treatment of disease caused by abnormal cell growth
JP6899201B2 (en) * 2016-06-23 2021-07-07 日東電工株式会社 Cell death inducer, cell proliferation inhibitor and therapeutic pharmaceutical composition for diseases caused by abnormal cell proliferation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160186183A1 (en) * 2014-12-26 2016-06-30 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
US20160186182A1 (en) * 2014-12-26 2016-06-30 Nitto Denko Corporation Rna interference compositions and methods for malignant tumors

Also Published As

Publication number Publication date
JP2019508379A (en) 2019-03-28
JP2019033741A (en) 2019-03-07
WO2018151840A2 (en) 2018-08-23

Similar Documents

Publication Publication Date Title
WO2016106404A3 (en) Methods and compositions for treating malignant tumors associated with kras mutation
NZ763275A (en) Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use
WO2019006418A3 (en) Adeno-associated viral vectors for gene therapy
PH12019501116A1 (en) Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20
AU2018341571A8 (en) Therapeutic methods relating to HSP90 inhibitors
WO2018140920A8 (en) Compositions and methods for inhibition of factor xii gene expression
EA201891268A1 (en) COMPOUNDS WHICH CAN BE USED AS KINASE INHIBITORS
EP4393495A3 (en) Programmed cell death 1 ligand 1 (pd-l1) irna compositions and methods of use thereof
WO2018098117A8 (en) SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
WO2021096763A8 (en) Methods and compositions for treating an angiotensinogen- (agt-) associated disorder
EA201900561A1 (en) CONJUGATES OF CYCLODEXTRIN-PROTEIN-MEDICINE
EA201890957A1 (en) COMBINED THERAPY FOR THE TREATMENT OF MALIGNANT TUMORS
BR112016028641A2 (en) ? method for treating cancer?
BR112023022481A2 (en) METHODS OF TREATMENT OF CANCERS WITH BIALLELIC LOSS OF FUNCTION MUTATION OR GENE OVEREXPRESSION
WO2020072126A3 (en) Modulating ptpn2 to increase immune responses and perturbing gene expression in hematopoietic stem cell lineages
EA201792103A1 (en) COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HIF2ALPH GENES
WO2020146521A3 (en) Rnai agents for inhibiting expression of hif-2 alpha (epas1), compositions thereof, and methods of use
IN2014DN08199A (en)
EP4410373A3 (en) Nucleic acid simultaneously inhibiting expression of mtor gene and stat3 gene
MX379585B (en) COMPOSITION FOR USE IN THE TREATMENT OF CANCER PRESENTING HEMICYGOUS LOSS OF TP53.
WO2023081500A3 (en) RNAi OLIGONUCLEOTIDE CONJUGATES
BR112014016723A2 (en) method for treating breast cancer
MX2022004524A (en) Gene therapy for alzheimer's disease.
BR112018011196A2 (en) use pyrimidine pyrimidazinones to treat cancer
WO2019075216A8 (en) Plectin-1 binding antibodies and uses thereof

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2018535394

Country of ref document: JP

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18754969

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18754969

Country of ref document: EP

Kind code of ref document: A2